Aprea Therapeutics Insiders Still US$86k Away From Original Investment Value

Insiders who bought US$176.1k worth of Aprea Therapeutics, Inc. (NASDAQ:APRE) stock in the last year have seen some of their losses recouped as the stock gained 11% last week. However, total losses seen by insiders are still US$86k since the time of purchase.

Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

The Last 12 Months Of Insider Transactions At Aprea Therapeutics

The Independent Director Marc Duey made the biggest insider purchase in the last 12 months. That single transaction was for US$132k worth of shares at a price of US$4.39 each. That means that an insider was happy to buy shares at above the current price of US$1.88. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Notably Marc Duey was also the biggest seller.

In the last twelve months insiders purchased 48.09k shares for US$176k. On the other hand they divested 6.46k shares, for US$30k. In total, Aprea Therapeutics insiders bought more than they sold over the last year. Their average price was about US$3.66. This is nice to see since it implies that insiders might see value around current prices. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

See our latest analysis for Aprea Therapeutics

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 12% of Aprea Therapeutics shares, worth about US$1.2m, according to our data. We do generally prefer see higher levels of insider ownership.

What Might The Insider Transactions At Aprea Therapeutics Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. The transactions are fine but it'd be more encouraging if Aprea Therapeutics insiders bought more shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Aprea Therapeutics. Be aware that Aprea Therapeutics is showing 3 warning signs in our investment analysis, and 1 of those doesn't sit too well with us...

Of course Aprea Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.